Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18376955 | 1.00 | IDH1 (1.00) | IDH1 | |
| SCHEMBL23280134 | 1.00 | IDH1 (1.00) | IDH1 | |
| SCHEMBL18376953 | 1.00 | IDH1 (1.00) | IDH1 | |
| SCHEMBL18376954 | 0.92 | IDH1 (1.00) | IDH1 | |
| SCHEMBL20397548 | 0.92 | IDH1 (1.00) | IDH1 | |
| SCHEMBL23280177 | 0.92 | IDH1 (1.00) | IDH1 | |
| SCHEMBL18376901 | 0.92 | IDH1 (1.00) | IDH1 | |
| SCHEMBL20414992 | 0.92 | IDH1 (1.00) | IDH1 | |
| SCHEMBL23280137 | 0.92 | IDH1 (1.00) | IDH1 | |
| SCHEMBL18376796 | 0.92 | IDH1 (1.00) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3319945-B1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2021-04-28 | — | — | EP | claimed |
| US-10179123-B2 | 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-15 | — | — | US | claimed |
| US-20180207137-A1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | US | claimed |
| EP-3319945-B1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2021-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207137-A1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | HRH1, MDN1, NAT1 | IDH1 44/4885 |
| US-10179123-B2 | 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors | HRH1, MDN1, NAT1 | IDH1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.